Introduction

For years, people took GLP-1 medications to lose weight or manage diabetes. The heart protection was a bonus , something researchers noticed in the data, not the reason anyone wrote a prescription. That changed.

In late 2023, the SELECT trial landed and fundamentally rewrote the conversation. Semaglutide , the active ingredient in Ozempic and Wegovy , reduced the risk of major cardiovascular events in people who did not even have diabetes. The finding was big enough that the FDA expanded Wegovy’s label in March 2024 to include cardiovascular risk reduction. For the first time, a GLP-1 medication was officially a heart drug.

If you take a GLP-1, or you are considering one, understanding what these medications do for your heart is not a side detail. It might be the most important part of the story.

Medical Disclaimer: This article is for informational purposes only. It does not constitute medical advice. Cardiovascular medications involve complex risk-benefit calculations that require individualized assessment. Do not start, stop, or change any medication without consulting your healthcare provider. If you are experiencing chest pain, shortness of breath, or other concerning symptoms, seek emergency care immediately.

The SELECT trial: What it found and why it matters

The SELECT trial , full name: Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity , enrolled 17,604 adults across 41 countries. Every participant had established cardiovascular disease (previous heart attack, stroke, or symptomatic peripheral artery disease). Every participant had a BMI of 27 or higher. And critically, none of them had diabetes PMID: 37952131.

That last detail is why SELECT changed the conversation. Prior to SELECT, every major GLP-1 cardiovascular outcomes trial had been conducted in people with type 2 diabetes. The cardiovascular benefit could plausibly have been driven entirely by improved glycemic control , controlling blood sugar, protecting the heart. SELECT tested whether semaglutide protects the heart independently of diabetes management.

It did.

Over a mean follow-up of 39.8 months, participants randomized to semaglutide 2.4 mg weekly experienced a 20% reduction in major adverse cardiovascular events (MACE) compared to placebo. That composite endpoint included cardiovascular death, nonfatal myocardial infarction (heart attack), and nonfatal stroke. The absolute risk reduction was 1.5 percentage points (6.5% vs. 8.0%). That translates to roughly one event prevented for every 67 people treated for about three years.

The individual components all trended in the same direction. Cardiovascular death dropped by 15%. Nonfatal heart attack fell by 28%. Nonfatal stroke decreased by 7%, though the confidence interval crossed 1.0, so the stroke finding alone did not reach independent statistical significance.

What made SELECT particularly convincing was that the curves started separating early , within the first few months , before substantial weight loss had occurred. The drug was doing something to the cardiovascular system that weight loss alone could not explain. Semaglutide reduced events in people who lost little weight as well as in people who lost a lot.

The safety profile matched what we already knew from the weight loss trials. More participants in the semaglutide group stopped treatment because of gastrointestinal side effects (16.6% vs. 8.2%). But serious adverse events were actually lower in the semaglutide group, driven largely by fewer cardiovascular events.

In March 2024, the FDA approved an updated label for Wegovy (semaglutide 2.4 mg) adding an indication “to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either overweight or obesity.” The agency did not restrict it to people who were also losing weight. The heart benefit was recognized as a direct drug effect.

Beyond Select: other cardiovascular outcome trials

SELECT was not the first cardiovascular outcomes trial for a GLP-1 receptor agonist, but it was the first in people without diabetes. The trials that came before it , all conducted in type 2 diabetes populations , laid the groundwork.

SUSTAIN-6 (2016)

SUSTAIN-6 randomized 3,297 people with type 2 diabetes and high cardiovascular risk to semaglutide (0.5 mg or 1.0 mg) or placebo. Over a median follow-up of 2.1 years, semaglutide reduced MACE by 26% , similar in magnitude to what SELECT would later report PMID: 27633186. The trial was not originally designed to prove cardiovascular superiority, but the signal was strong enough that it prompted regulators and researchers to take notice. The biggest driver was a 39% reduction in nonfatal stroke, a finding that contributed to a favorable benefit-risk assessment by both the FDA and EMA.

PIONEER-6 (2019)

PIONEER-6 tested oral semaglutide (the pill form, marketed as Rybelsus) in 3,183 people with type 2 diabetes and high cardiovascular risk. Over a median follow-up of 15.9 months, oral semaglutide reduced MACE by 21% compared to placebo PMID: 31185157. The trial was designed as a preapproval cardiovascular safety study, not a superiority trial, so the endpoint was noninferiority , and it passed handily. The 21% reduction was consistent with what injectable semaglutide had shown in SUSTAIN-6, suggesting the cardiovascular benefit is a class effect that translates across administration routes.

LEADER (2016)

LEADER tested liraglutide, an earlier GLP-1 receptor agonist, in 9,340 people with type 2 diabetes and high cardiovascular risk. Liraglutide reduced MACE by 13% over 3.8 years. The cardiovascular death reduction was particularly notable at 22% PMID: 27295427. LEADER was the first GLP-1 cardiovascular outcomes trial to show a mortality benefit, and it established that the class was not just safe , it was protective.

REWIND (2019)

REWIND tested dulaglutide, a once-weekly GLP-1 receptor agonist, in 9,901 people with type 2 diabetes. Dulaglutide reduced MACE by 12% over 5.4 years PMID: 31189511. Importantly, only 31% of participants had established cardiovascular disease at baseline , most had risk factors alone. REWIND demonstrated that the cardiovascular benefit extends to primary prevention populations, not just people who have already had a heart attack or stroke.

STEP-HFpEF (2023)

STEP-HFpEF tested semaglutide in people with heart failure with preserved ejection fraction (HFpEF) and obesity , a population notoriously difficult to treat. Over 52 weeks, semaglutide produced clinically meaningful improvements in symptoms, physical limitations, and exercise function. People could walk farther. They felt better. Their inflammatory markers dropped. Their NT-proBNP levels fell PMID: 37622681. This was not a hard-outcomes trial , it was not powered for death or hospitalization , but it showed that GLP-1 receptor activation improves the lived experience of heart failure.

How GLP-1s protect the Heart: mechanisms beyond weight loss

The naive answer is that GLP-1 medications help people lose weight, and weight loss is good for the heart. That is true, but incomplete. The SELECT trial showed event curves separating within months , long before substantial weight loss occurred. Something else is happening.

GLP-1 receptors are found throughout the cardiovascular system: on endothelial cells lining blood vessels, on cardiomyocytes (heart muscle cells), on vascular smooth muscle, and on immune cells that infiltrate atherosclerotic plaques. When semaglutide or liraglutide binds to these receptors, several things happen simultaneously.

Atherosclerosis slows down. GLP-1 receptor activation reduces the inflammatory signaling that drives plaque formation and destabilization. In animal models, GLP-1 agonists shrink plaque size and stabilize existing plaques so they are less likely to rupture and cause a heart attack or stroke. Human imaging studies with carotid ultrasound and coronary CT angiography have shown slower plaque progression.

Blood pressure drops, modestly but meaningfully. GLP-1 receptor agonists reduce systolic blood pressure by 2 to 6 mmHg, partly through weight loss, partly through direct vasodilation and natriuresis (sodium excretion). A sustained 5 mmHg reduction in population-level systolic blood pressure translates to roughly a 10% reduction in major cardiovascular events. This is not the whole story, but it is part of it.

Inflammation dials down. GLP-1 receptor activation reduces C-reactive protein (CRP) and other inflammatory markers independently of weight loss. SELECT showed CRP reductions of roughly 40% from baseline. Chronic low-grade inflammation is a central driver of atherosclerosis, and GLP-1s appear to interrupt that pathway directly.

Endothelial function improves. The endothelium , the single-cell lining of blood vessels , regulates vascular tone, clotting, and inflammation. In people with obesity or diabetes, endothelial function is impaired. GLP-1 receptor activation restores endothelial function, improving the ability of blood vessels to dilate when needed.

Platelet aggregation may decrease. There is preclinical evidence that GLP-1 receptor agonists reduce platelet reactivity, potentially lowering the risk of arterial clot formation. The clinical significance of this mechanism in humans is still being studied.

The cumulative picture is that GLP-1 medications hit cardiovascular risk through multiple independent pathways, not just through weight loss or glucose control. They are pleiotropic , acting on many systems at once. And that multiplicity of mechanisms is likely why the signal is so consistent across trials.

Who benefits most?

The cardiovascular benefit of GLP-1 receptor agonists appears to be broad, but not uniform.

People with established cardiovascular disease benefit the most in absolute terms. In SELECT, the absolute risk reduction was 1.5 percentage points over roughly three years, and that number grows with longer treatment duration. If you have already had a heart attack or stroke, the case for a GLP-1 is strong , provided you also have overweight or obesity.

People with type 2 diabetes are the best-studied population. The meta-analyses are clear: across SUSTAIN-6, LEADER, REWIND, PIONEER-6, and others, GLP-1 receptor agonists reduce MACE by 12 to 14% in people with diabetes PMID: 33862008. The benefit is consistent across age groups, baseline HbA1c levels, and background medication use.

People with heart failure with preserved ejection fraction (HFpEF) and obesity now have evidence that semaglutide improves symptoms, exercise capacity, and quality of life. This is a population that has had frustratingly few effective treatments, and the STEP-HFpEF results have changed practice at many heart failure centers.

The question of primary prevention , treating people who have risk factors but no established disease , is less settled. REWIND enrolled mostly primary prevention patients with diabetes and saw a MACE reduction. SELECT required established cardiovascular disease for enrollment. Ongoing trials are exploring primary prevention in people with overweight or obesity but no diabetes and no known cardiovascular disease, and those results will fill an important evidence gap.

Heart attack, stroke, and Death: the numbers

Let me put the numbers in one place, because they are worth seeing side by side.

In SELECT, the individual component results were:

  • Cardiovascular death: 15% relative reduction (HR 0.85, 95% CI 0.71–1.01). This narrowly missed statistical significance as a standalone endpoint but contributed importantly to the composite outcome.
  • Nonfatal myocardial infarction (heart attack): 28% reduction (HR 0.72, 95% CI 0.61–0.85). This was the strongest individual signal and was highly statistically significant.
  • Nonfatal stroke: 7% reduction (HR 0.93, 95% CI 0.74–1.15). The direction was favorable but the confidence interval was wide.

Across the class, the Sattar meta-analysis of eight cardiovascular outcomes trials including over 60,000 participants found PMID: 33862008:

  • MACE: 14% reduction (HR 0.86, 95% CI 0.80–0.93)
  • All-cause mortality: 12% reduction (HR 0.88, 95% CI 0.82–0.94)
  • Cardiovascular death: 13% reduction (HR 0.87, 95% CI 0.79–0.96)
  • Fatal or nonfatal stroke: 16% reduction (HR 0.84, 95% CI 0.76–0.93)
  • Fatal or nonfatal myocardial infarction: 10% reduction (HR 0.90, 95% CI 0.80–1.01)
  • Heart failure hospitalization: 11% reduction (HR 0.89, 95% CI 0.78–1.01)

These are class-level estimates, meaning they average across different GLP-1 drugs, different populations, and different follow-up durations. The consistency across trials, across drugs, and across populations is what gives researchers confidence that the effect is real.

Does this mean Ozempic Is a heart medication?

Yes and no. The FDA says yes , Wegovy (semaglutide 2.4 mg) now carries an approved indication for cardiovascular risk reduction. That makes it, by regulatory definition, a cardiovascular medication. But the picture is more nuanced in practice.

Semaglutide was developed as a diabetes drug, then repurposed as a weight loss drug, and is now also a cardiovascular drug. The same molecule does all three things. That is unusual in pharmacology, but it reflects the shared biology: the metabolic, weight, and cardiovascular systems are not separate departments in the body. They are the same system.

For a person with obesity and a history of heart attack, semaglutide offers three layers of benefit: weight loss, glycemic improvement, and direct cardiovascular protection. These are not competing effects. They are additive.

The practical question is whether cardiologists will prescribe GLP-1s directly. In 2026, the answer is increasingly yes. Major cardiology societies, including the American Heart Association and the European Society of Cardiology, have updated guidelines to include GLP-1 receptor agonists in the management of cardiovascular risk in people with overweight or obesity. But prescribing is still concentrated among endocrinologists and primary care. The diffusion into cardiology practice is happening, but slowly.

What this means for you if you’re taking a GLP-1

If you are already on a GLP-1 medication for weight loss or diabetes, the cardiovascular data is good news , but it is not a free pass.

Here is what the evidence means practically. Taking semaglutide (or liraglutide, or dulaglutide) reduces your risk of heart attack, stroke, and cardiovascular death by roughly 12 to 20 percent, depending on your baseline risk. That is a meaningful number. For someone at high baseline risk , say, a person with established coronary artery disease , this could prevent one in every few dozen treated patients from having a major cardiovascular event over a few years.

But the medication does not eliminate risk. It reduces it. You still need to manage blood pressure. You still benefit from statin therapy if indicated. You still need to quit smoking, move your body, and attend to the other fundamentals of cardiovascular health. GLP-1 agonists are an addition to the toolkit, not a replacement for it.

The gastrointestinal side effects are real, and they cause some people to stop the medication. If you are tolerating it well, the cardiovascular data gives you one more reason to continue. If you are struggling with side effects, talk to your doctor , but do not assume the drug is optional. For many people, the cardiovascular math makes continued use the right call even if the side effects are inconvenient.

Blood pressure and cholesterol effects

The blood pressure and cholesterol data deserve their own discussion, because they help explain the cardiovascular outcomes but also raise important clinical questions.

Blood pressure. Across clinical trials, semaglutide reduces systolic blood pressure by 4 to 6 mmHg and diastolic by 1 to 3 mmHg. In SELECT, the reduction was approximately 3.3 mmHg systolic at two years, persisting through the trial. This effect is partly mediated by weight loss , every kilogram lost drops blood pressure by roughly 1 mmHg , but the timing and magnitude suggest a weight-independent component.

Ambulatory blood pressure monitoring studies have confirmed that the reduction is sustained across 24 hours, not just a clinic measurement artifact. The drop is modest, but sustained, and at the population level, a sustained 5 mmHg reduction in systolic blood pressure translates into meaningful reductions in stroke and coronary events.

Cholesterol. The lipid effects are more modest. Semaglutide tends to reduce triglycerides and slightly lower LDL cholesterol, but the changes are usually in the range of 5 to 10 percent , smaller than what statins achieve. In SELECT, LDL cholesterol fell by about 3 percent more in the semaglutide group than placebo. The cardiovascular benefit of GLP-1s does not appear to run primarily through lipid pathways.

Heart rate. One consistent finding across GLP-1 trials is a small increase in resting heart rate , typically 2 to 4 beats per minute. The mechanism is not fully understood but may involve sympathetic nervous system activation or direct sinoatrial node effects. This increase is not associated with adverse outcomes , cardiovascular events still go down despite the heart rate bump , but it is something your doctor may notice on your vital signs and should not cause alarm.

Remaining questions and ongoing trials

For all the progress, important questions remain open in 2026.

Do GLP-1s prevent cardiovascular events in primary prevention , people with obesity but no prior events and no diabetes? SELECT required established cardiovascular disease for enrollment. Ongoing trials including SOUL (oral semaglutide) and EVOKE are exploring broader populations, and their results will determine whether the cardiovascular indication expands further.

What about tirzepatide? Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist that produces even greater weight loss than semaglutide. The SURPASS-CVOT trial is testing tirzepatide’s cardiovascular outcomes in people with type 2 diabetes, and the SURMOUNT-MMO trial is testing cardiovascular outcomes in people with obesity but no diabetes. Results are expected in the next few years and will likely shape prescribing patterns significantly.

Is the cardiovascular benefit a class effect? The evidence strongly suggests yes. Liraglutide, semaglutide (injectable and oral), dulaglutide, and even the shorter-acting agents have all shown favorable cardiovascular signals. But the effect sizes vary, and the longer-acting agents (semaglutide, dulaglutide) appear to have larger effects than shorter-acting ones (lixisenatide, exenatide). Whether this is a drug-specific difference or a reflection of trial design and population differences is still debated.

What happens if you stop? The cardiovascular benefit of GLP-1 receptor agonists likely requires continued treatment. When the drug is stopped, weight returns, blood pressure climbs, and the anti-inflammatory and anti-atherosclerotic effects presumably fade. Long-term discontinuation studies with cardiovascular endpoints do not exist, but the biology suggests these are chronic therapies for a chronic condition.

Can GLP-1s be combined with SGLT2 inhibitors for additive cardiovascular benefit? SGLT2 inhibitors (empagliflozin, dapagliflozin) also reduce cardiovascular events and heart failure hospitalizations, but through different mechanisms. Combination therapy is biologically plausible and increasingly common in diabetes management. Dedicated cardiovascular outcomes trials testing the combination are needed.

Frequently asked questions

Does Ozempic prevent heart attacks in people who don’t have diabetes?

Yes. The SELECT trial showed that semaglutide 2.4 mg reduced nonfatal heart attack by 28% in people with cardiovascular disease and overweight or obesity, regardless of diabetes status. This was the basis for the FDA’s expanded cardiovascular indication.

How long do you need to take a GLP-1 to get heart protection?

The SELECT curves started separating within the first few months of treatment. But the benefit accumulates over time , the longer you take it, the more events are prevented. This is likely a chronic therapy, not a short course.

Does the heart benefit come from weight loss?

Only partially. The SELECT trial showed that event curves separated before substantial weight loss occurred, and the benefit was similar across different degrees of weight loss. GLP-1s have direct cardiovascular effects that are independent of weight reduction.

Is semaglutide better for the heart than liraglutide or dulaglutide?

Direct head-to-head cardiovascular outcomes trials do not exist. Semaglutide showed larger effect sizes in its trials than liraglutide or dulaglutide did in theirs, but cross-trial comparisons are unreliable. The available evidence supports all three as cardioprotective agents.

Can I take a statin and a GLP-1 together for additive heart protection?

Yes. Statins and GLP-1 receptor agonists work through different mechanisms, and there is no known adverse interaction between them. In the SELECT trial, 90% of participants were on statins, and semaglutide reduced cardiovascular events on top of that background therapy.

Does Rybelsus (oral semaglutide) protect the heart?

The PIONEER-6 trial showed a 21% reduction in MACE with oral semaglutide compared to placebo in people with type 2 diabetes at high cardiovascular risk. The confidence interval was wide, and the trial was not powered for superiority, but the direction and magnitude are consistent with the injectable form.

References

  1. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131

  2. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. PMID: 27633186

  3. Husain M, Birkenfeld AL, Donsmark M, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381(9):841-851. PMID: 31185157

  4. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069-1084. PMID: 37622681

  5. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. PMID: 27295427

  6. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-130. PMID: 31189511

  7. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653-662. PMID: 33862008